Oxytocin and Fetal Heart Rate Changes

• Status: Recruiting
• Trial end date: 2022-04-30
• Target enrollment: 0
• Participant gender: Female

Summary

The reported risk of nonreassuring fetal heart trace following neuraxial analgesia is 3-23%. This variability may be due to fluid and oxytocin management prior to and during the initiation of neuraxial analgesia. The study hypothesis is that decreasing the oxytocin infusion rate by 50 % prior to initiation of combined spinal epidural analgesia will cause a reduction in the incidence of adverse fetal heart rate changes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Iowa; Unyime Ituk
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

• Healthy nulliparous or multiparous women at term (37 > weeks' gestation)

• Singleton pregnancy

• Request for neuraxial analgesia

• Oxytocin used for induction of labor or augmentation of labor per institutional protocols

Exclusion Criteria:

• Use of chronic analgesic medications

• Prior administration of systemic opioid labor analgesia

• Non-vertex presentation

• Contraindication to neuraxial analgesia

• Category 3 fetal heart rate tracing prior to the initiation of combined spinal epidural analgesia